Vivoryon Therapeutics N.V. · EURONEXT:VVY
Vivoryon Therapeutics — Investor Presentation (February 2024)
19 slides from Vivoryon Therapeutics's investor presentation, February 2024
Slide 1: Upstream intervention to address multiple hallmarks of AD
Upstream intervention to address multiple hallmarks of AD Tackling AD at the roots |Vivoryon Therapeutics N.V. – February 2024
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Vivoryon is Uniquely Positioned to Improve Health Outcome in Patients with Early Alzheimer's Disease
Vivoryon is Uniquely Positioned to Improve Health Outcome in Patients with Early Alzheimer’s Disease Unique First-in-Class Approach Robust Development Program Proven Team of Innovators Stops production of neurotoxic Phase 2 studies progressing well Strong discovery and development N3pE-amyloid ◆ Val
Slide 4: Seasoned Executive Team Equipped with Expertise in Drug Development
Seasoned Executive Team Equipped with Expertise in Drug Development EXECUTIVE DIRECTORS NON-EXECUTIVE DIRECTORS Frank Weber, MD Erich Platzer, MD, PhD Chief Executive Officer/Chief Medical Officer Chairman of the Board Kugan Sathiyanandarajah Vice-Chairman & Chair Compensation Committee Michael Scha
Slide 5: Multiple Inflection Points for Lead Asset Varoglutamstat
Multiple Inflection Points for Lead Asset Varoglutamstat, Research Activities Provide Further Opportunities for Future Growth Program Approach Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Status VIVIAD: Fully recruited; Final readout Varoglutamstat SMI VIVIAD: Ph2b in EU during end Q1/24
Slide 6: AD Landscape: Growing Incidence Rate and High Disease Burden on Patient Care Ecosystem
AD Landscape: Growing Incidence Rate and High Disease Burden on Patient Care Ecosystem ~55 Million Worldwide Living with Dementia1 AD is the most common form of dementia and may contribute to Projected number of people age 65 and older (total and by age) 60–70% of cases1 in the U.S. population with
Slide 7: Despite Recent AD Treatment Successes Early AD Unmet Need Remains High
Despite Recent AD Treatment Successes Early AD Unmet Need Remains High Unmet Need Remains High for Early Varoglutamstat Has Potential to Fill AD Patients the Gaps • Improved safety and higher efficacy in • Potential for higher safety and better early (MCI) patients efficacy compared to SOC • Robust
Slide 8: Our Lead Product Candidate, Varoglutamstat, Targets Multiple Key Hallmarks of Alzheimer's Disease
Our Lead Product Candidate, Varoglutamstat, Targets Multiple Key Hallmarks of Alzheimer’s Disease Early in Pathological Process ROLE OF QPCT/L IN AD PATHOLOGY VAROGLUTAMSTAT TARGETS AD PATHOGENESIS EARLY-ON Increased activity of glutaminyl cyclase (QPCT) is Abeta CCL2 associated with AD pathology in
Slide 9: Translating In Vivo Evidence for Relevance of QPCT/L Inhibition into Human AD
Translating In Vivo Evidence for Relevance of QPCT/L Inhibition into Human AD Abeta Pathology QPCT is essential for N3pE amyloid formation in vivo1 Dose-dependent reduction of QPCT 5XFAD mice, QPCT ko and tg QPCT/ N3pE activity in CSF & serum (Ph1 + Ph2a) Neuroinflammation CCL2 activity promotes Tau
Slide 10: Building Comprehensive Robust Clinical Evidence Including Well-designed Phase 2b Program
Building Comprehensive Robust Clinical Evidence Including Well-designed and Well-powered Placebo-controlled Phase 2b Program • Dose range: 10-1800 mg single dose; 20-800 mg BID Phase 1 205 volunteers ü • • CSF based PK/PD model Fed / fasted and 3 formulations • 12w of treatment Phase 2a 120 patients
Slide 11: Completed Phase 2a SAPHIR Study Provides Evidence of Significant Changes in Working Memory
Completed Phase 2a SAPHIR Study Provides Evidence of Significant Changes in Working Memory and Synaptic Recovery after only 12 Weeks of Treatment Significant Changes in Recovery EEG Reduction of Working Memory1 Synaptic Activity1,2 Neuronal Injury Biomarker1 P=0.05 Placebo Varoglutamstat Alpha wave
Slide 12: VIVIAD Phase 2b European Study Assesses Safety, Tolerability and Efficacy
VIVIAD Phase 2b European Study Assesses Safety, Tolerability and Efficacy of Varoglutamstat in Patients with MCI and Mild AD1,2 4 12 16 24 INTERIM SAFETY 36 48 60 72 84-96 FINAL DATA Site visits Mid-22 1Q24 w 13-24 FIRST 90 PATIENTS 1:1:1 DSMB DECISION w 25–48/96 Placebo / 300 mg / 600 mg Safety / F
Slide 13: VIVIAD Phase 2b: Inclusion Criteria Enabled Precision Recruitment
VIVIAD Phase 2b: Inclusion Criteria Enabled Precision Recruitment Recruiting the right patients with early AD is a critical success factor for VIVIAD BASIC REQUIREMENT: ◆ Mandatory for inclusion: all patients had low Abeta and high p-tau CSF values (Elecsys/Roche) RETHINKING MCI ASSESSMENT: ◆ Precis
Slide 14: VIVIAD Update: Discontinuation Rates are Favorable and Comparably Low
VIVIAD Update: Discontinuation Rates are Favorable and Comparably Low Varoglutamstat Lecanemab Donanemab Metric VIVIAD CLARITY AD TRAILBLAZER ALZ 2 Observations: (blinded) (placebo/active) combined tau (placebo/active) ◆ Total number of discontinuations remains low in VIVIAD throughout the study at
Slide 15: Delivering Key Results Through Well-Designed VIVIAD Study
Delivering Key Results Through Well-Designed VIVIAD Study Primary and comprehensive secondary endpoints data package in Q1/24 Can varoglutamstat Can varoglutamstat improve improve cognition? activities of daily living? Endpoints: Endpoint: N FU Cogstate NTB* (primary/secondary) O NC A-IADL-Q (key se
Slide 16: VIVA-MIND Update: Recent DSMB Decision Leads to Progress
VIVA-MIND Update: Recent DSMB Decision Leads to Progress and Enables Further Study Design Flexibility v Ongoing Phase 2 study running in parallel to VIVIAD to provide clear picture of cognitive changes and support Vivoryon’s regulatory strategy v Adaptive study design involving titration, futility a
Slide 17: Leveraging Core Expertise in QPCT/L Oral Small Molecule Inhibitors
Leveraging Core Expertise in QPCT/L Oral Small Molecule Inhibitors to Generate Multiple Avenues of Addressing Unmet Need ALZHEIMER‘S DISEASE CHRONIC KIDNEY DISEASE Established program in Early AD with varoglutamstat VIVIAD provides unique opportunity to assess including product life cycle management
Slide 18: Core Asset Varoglutamstat Well-Positioned to be a Leader in QPCT/L for Early AD
Core Asset Varoglutamstat Well-Positioned to be a Leader in QPCT/L for Early AD, Future Opportunities Build on AD and Go Beyond Aiming for first line single VIVIAD learnings to inform Multiple value-generating agent treatment of future opportunities in AD and catalysts ahead patients with early AD a
Slide 19: Vivoryon Therapeutics N.V. contact details
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale) Germany Munich Franz-Josef-Delonge-Str. 5 81249 München Germany info@vivoryon.com +49 (0)345 555 99 00 www.vivoryon.com
Vivoryon Therapeutics — Investor Presentation (February 2024) on 6ix